Summary
Eli Lilly and Company (LLY) announced on April 24, 2020, its entry into an Underwriting Agreement to issue and sell $1,000,000,000 aggregate principal amount of 2.250% Notes due 2050. This offering is a debt financing activity, not related to new product development or clinical trial updates, which are typically key investor concerns. The net proceeds after underwriter discounts are expected to be approximately $988.6 million. Investors should note that the company is raising a significant amount of capital through long-term debt. The primary purpose of this filing is to disclose the terms of this debt issuance. While the filing does not provide details on the use of proceeds, such financings are generally undertaken to support ongoing operations, potential acquisitions, or capital expenditures. The maturity date of May 15, 2050, indicates a long-term commitment from the company to repay this debt.
Key Highlights
- 1Eli Lilly (LLY) is issuing $1 billion in 2.250% senior notes maturing in 2050.
- 2The net proceeds from the offering are expected to be approximately $988.6 million after underwriter discounts.
- 3The offering is registered under a Form S-3ASR registration statement.
- 4The notes will accrue interest at 2.250% per annum, payable semi-annually.
- 5The company has the option to redeem the notes, in whole or in part, under specific conditions.
- 6The closing of the offering is anticipated to occur on May 5, 2020.
- 7This is a debt financing event, not a disclosure of operational or clinical progress.